Two New Opioid REMS CE Data Reports

The ACCME has released two new data reports showing the scope of continuing education (CE) activities offered by accredited providers within the ACCME System in support of the US Food and Drug Administration (FDA)  Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategies (ER/LA REMS) and Opioid Analgesic Risk Evaluation and Mitigation Strategy (OA REMS).

The 2019 Report on ER/LA Opioid REMS CME Activities in PARS shows that 108 accredited providers in the ACCME System reported 943 REMS-compliant activities educating more than 430,000 learners across the country. The report includes information about the geographic distribution of activities, the activity types, the provider types, the learner professions, the percentages of activities designed and analyzed for changes in competence, performance, or patient outcomes, and a list of the participating CE providers. 

In 2018, the FDA launched the Opioid Analgesic REMS which expanded the program to include Immediate-Release (IR) opioids. New this year, the 2019 Report on Opioid Analgesic REMS CME Activities in PARS shows that 14 accredited providers have reported 64 Opioid Analgesic REMS CME activities. As of July 31, 2019, providers have offered 36 activities, which were completed by more than 18,000 learners; 28 activities are planned for the future. This report also includes information about the activity types, the provider types, the learner professions, and a list of the participating CE providers. 

The data reports are made possible by the voluntary submission of ER/LA Opioid REMS and Opioid Analgesic REMS data by accredited providers into ACCME’s Program and Activity Reporting System (PARS). As a service to the CME community and to the FDA, the ACCME modified PARS to enable accredited providers to submit information specific to the REMS continuing medical education activities they provide. 

Download the 2019 reports below:

For more information, visit our CME in Support of REMS webpage